UPDATE: Correction - Canaccord Genuity Maintains a 'Buy' on Incyte (INCY); Q2 and Guidance Raises Several Questions
Tweet Send to a FriendGet Alerts INCY Hot Sheet
Price: $21.41 +1.66%
Rating Summary:
10 Buy, 4 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 1 | New: 1
Rating Summary:
10 Buy, 4 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 1 | New: 1
Trade INCY Now!
(Updated - August 3, 2012 10:29 AM EDT)
Correction - Canaccord Genuity maintains a 'Buy' on Incyte (NASDAQ: INCY) price target of $25.00.
Analyst, Salveen Richter, said, "Q2 Jakafi net revenue of $32.7M (sell-in method) suggests $65.4M in H2 at the current run-rate (with no patient additions or discontinuations) vs. the $64.3M required to meet the low end of guidance. We believe it raises the following questions: 1) Was Q4/11 and Q1/12 growth driven by a bolus of MF patients, specifically those that were severe (unable to join the COMFORT trials) indicating a lower new patient addition rate going forward?; 2) a higher discontinuation rate? (INCY expects it to be above the 14% (24 wks) to 18% (48 wks) seen in P3, likely 20-25%); and 3) conservative FY12 guidance? While all factors are likely playing some role in guidance, we believe management is opting for conservatism."
For an analyst ratings summary and ratings history on Incyte click here. For more ratings news on Incyte click here.
Shares of Incyte closed at $19.57 yesterday, with a 52 week range of $11.76-$26.30.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Correction - Canaccord Genuity maintains a 'Buy' on Incyte (NASDAQ: INCY) price target of $25.00.
Analyst, Salveen Richter, said, "Q2 Jakafi net revenue of $32.7M (sell-in method) suggests $65.4M in H2 at the current run-rate (with no patient additions or discontinuations) vs. the $64.3M required to meet the low end of guidance. We believe it raises the following questions: 1) Was Q4/11 and Q1/12 growth driven by a bolus of MF patients, specifically those that were severe (unable to join the COMFORT trials) indicating a lower new patient addition rate going forward?; 2) a higher discontinuation rate? (INCY expects it to be above the 14% (24 wks) to 18% (48 wks) seen in P3, likely 20-25%); and 3) conservative FY12 guidance? While all factors are likely playing some role in guidance, we believe management is opting for conservatism."
For an analyst ratings summary and ratings history on Incyte click here. For more ratings news on Incyte click here.
Shares of Incyte closed at $19.57 yesterday, with a 52 week range of $11.76-$26.30.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
- Goldman Sachs Upgrades Enbridge (ENB) to Conviction Buy
- Steel Dynamics (STLD) Q2 Guidance Worse than Feared
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
Needham & Company, Canaccord Genuity
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
